Works by Dong-Wan Kim

Results: 298
    1

    Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.

    Published in:
    2017
    By:
    • Yu Jin Lim;
    • Ji Hyun Chang;
    • Hak-Jae Kim;
    • Keam, Bhumsuk;
    • Tae Min Kim;
    • Dong-Wan Kim;
    • Jin Chul Paeng;
    • Keon Wook Kang;
    • June-Key Chung;
    • Yoon Kyung Jeon;
    • Doo Hyun Chung;
    • Hong-Gyun Wu;
    • Lim, Yu Jin;
    • Chang, Ji Hyun;
    • Kim, Hak-Jae;
    • Kim, Tae Min;
    • Kim, Dong-Wan;
    • Paeng, Jin Chul;
    • Kang, Keon Wook;
    • Chung, June-Key
    Publication type:
    journal article
    2
    3

    Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.

    Published in:
    2016
    By:
    • Koung Jin Suh;
    • Bhumsuk Keam;
    • Miso Kim;
    • Young Sik Park;
    • Tae Min Kim;
    • Yoon Kyung Jeon;
    • Dong-Wan Kim;
    • Doo Hyun Chung;
    • Young Whan Kim;
    • Dae Seog Heo;
    • Suh, Koung Jin;
    • Keam, Bhumsuk;
    • Kim, Miso;
    • Park, Young Sik;
    • Kim, Tae Min;
    • Jeon, Yoon Kyung;
    • Kim, Dong-Wan;
    • Chung, Doo Hyun;
    • Kim, Young Whan;
    • Heo, Dae Seog
    Publication type:
    journal article
    4

    Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.

    Published in:
    2021
    By:
    • Park, Keunchil;
    • Jӓnne, Pasi A.;
    • Kim, Dong‐Wan;
    • Han, Ji‐Youn;
    • Wu, Ming‐Fang;
    • Lee, Jong‐Seok;
    • Kang, Jin‐Hyoung;
    • Lee, Dae Ho;
    • Cho, Byoung Chul;
    • Yu, Chong‐Jen;
    • Pang, Yong Kek;
    • Felip, Enriqueta;
    • Kim, Hyunjin;
    • Baek, Eunhye;
    • Noh, Young Su;
    • Kim, Dong-Wan;
    • Han, Ji-Youn;
    • Wu, Ming-Fang;
    • Lee, Jong-Seok;
    • Kang, Jin-Hyoung
    Publication type:
    journal article
    5
    6

    Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.

    Published in:
    Clinical Lung Cancer, 2022, v. 23, n. 8, p. 720, doi. 10.1016/j.cllc.2022.07.008
    By:
    • Myung J. Ahn;
    • Hye R. Kim;
    • Yang, James C. H.;
    • Ji-Yu Han;
    • Yu-Chung. Li, Jacky;
    • Hochmair, Maximilian J.;
    • Gee-Chen Chang;
    • Delmonte, Angelo;
    • Ki H. Lee;
    • Campelo, Rosario G.;
    • Gridelli, Cesare;
    • Spira, Alexander I.;
    • Califano, Raffaele;
    • Griesinger, Frank;
    • Ghosh, Sharmistha;
    • Felip, Enriqueta;
    • Dong-Wan Kim;
    • Yuyin Liu;
    • Pingkuan Zhang;
    • Popat, Sanjay
    Publication type:
    Article
    7

    Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.

    Published in:
    Clinical Lung Cancer, 2022, v. 23, n. 8, p. 670, doi. 10.1016/j.cllc.2022.07.012
    By:
    • Myung-Ju Ahn;
    • Mendoza, Marvin Jonne L.;
    • Pavlakis, Nick;
    • Terufumi Kato;
    • Soo, Ross A.;
    • Dong-Wan Kim;
    • Chong Kin Liam;
    • Te-Chun Hsia;
    • Chee Khoon Lee;
    • Thanyanan Reungwetwattana;
    • Sarayut Geater;
    • Siu Hong Chan, Oscar;
    • Naiyarat Prasongsook;
    • Solomon, Benjamin J.;
    • Thi Thai Hoa Nguyen;
    • Toshiyuki Kozuki;
    • Chih-Hsin Yang, James;
    • Yi-Long Wu;
    • Shu Kam Mok, Tony;
    • Shao-Weng Tan, Daniel
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies.

    Published in:
    Lung Cancer: Targets & Therapy, 2019, v. 10, p. 125, doi. 10.2147/LCTT.S209231
    By:
    • Gadgeel, Shirish;
    • Shaw, Alice T;
    • Barlesi, Fabrice;
    • Crino, Lucio;
    • Yang, James CH;
    • Dingemans, Anne-Marie;
    • Kim, Dong-Wan;
    • Marinis, Filippo de;
    • Schulz, Mathias;
    • Liu, Shiyao;
    • Gupta, Ravindra;
    • Smoljanovic, Vlatka;
    • Ou, Sai-Hong Ignatius
    Publication type:
    Article
    25
    26
    27
    28

    Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

    Published in:
    Cancer Research & Treatment, 2024, v. 56, n. 1, p. 48, doi. 10.4143/crt.2023.453
    By:
    • Ki Hyeong Lee;
    • Byoung Chul Cho;
    • Myung-Ju Ahn;
    • Yun-Gyoo Lee;
    • Youngjoo Lee;
    • Jong-Seok Lee;
    • Joo-Hang Kim;
    • Young Joo Min;
    • Gyeong-Won Lee;
    • Sung Sook Lee;
    • Kyung-Hee Lee;
    • Yoon Ho Ko;
    • Byoung Yong Shim;
    • Sang-We Kim;
    • Sang Won Shin;
    • Jin-Hyuk Choi;
    • Dong-Wan Kim;
    • Eun Kyung Cho;
    • Keon Uk Park;
    • Jin-Soo Kim
    Publication type:
    Article
    29
    30

    Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis.

    Published in:
    Cancer Research & Treatment, 2023, v. 55, n. 1, p. 83, doi. 10.4143/crt.2021.1571
    By:
    • Byoung Chul Cho;
    • Dong-Wan Kim;
    • Ullas Batra;
    • Keunchil Park;
    • Sang-We Kim;
    • Cheng-Ta Yang;
    • Pei-Jye Voon;
    • Virote Sriuranpong;
    • K. Govind Babu;
    • Khalid Amin;
    • Yingbo Wang;
    • Paramita Sen;
    • Khemaies Slimane;
    • Sarayut Geater
    Publication type:
    Article
    31
    32
    33

    Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.

    Published in:
    Cancer Research & Treatment, 2020, v. 52, n. 4, p. 1112, doi. 10.4143/crt.2020.245
    By:
    • Sun Min Lim;
    • Sang-We Kim;
    • Byoung Chul Cho;
    • Jin Hyung Kang;
    • Myung-Ju Ahn;
    • Dong-Wan Kim;
    • Young-Chul Kim;
    • Jin Soo Lee;
    • Jong-Seok Lee;
    • Sung Yong Lee;
    • Keon Uk Park;
    • Ho Jung An;
    • Eun Kyung Cho;
    • Tae Won Jang;
    • Bong-Seog Kim;
    • Joo-Hang Kim;
    • Sung Sook Lee;
    • Im-II Na;
    • Seung Soo Yoo;
    • Ki Hyeong Lee
    Publication type:
    Article
    34
    35
    36
    37
    38

    Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.

    Published in:
    Cancer Research & Treatment, 2019, v. 51, n. 1, p. 119, doi. 10.4143/crt.2018.019
    By:
    • Dong-Wan Kim;
    • Hoon-Gu Kim;
    • Joo-Hang Kim;
    • Keunchil Park;
    • Hoon-Kyo Kim;
    • Joung Soon Jang;
    • Bong-Seog Kim;
    • Jin-Hyoung Kang;
    • Kyung Hee Lee;
    • Sang-We Kim;
    • Hun Mo Ryoo;
    • Jin-Soo Kim;
    • Ki Hyeong Lee;
    • Jung Hye Kwon;
    • Jin-Hyuk Choi;
    • Sang Won Shin;
    • Seokyung Hahn;
    • Dae Seog Heo
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45

    Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

    Published in:
    Cancer Research & Treatment, 2016, v. 48, n. 2, p. 458, doi. 10.4143/crt.2015.135
    By:
    • Jin Hyoung Kang;
    • Myung-Ju Ahn;
    • Dong-Wan Kim;
    • Eun Kyung Cho;
    • Joo-Hang Kim;
    • Sang Won Shin;
    • Xin Wang;
    • Jong Seok Kim;
    • Mauro Orlando;
    • Keunchil Park
    Publication type:
    Article
    46
    47
    48
    49
    50